The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking

P Mazot1, A Cazes, M C Boutterin

  • 1Université Pierre et Marie Curie, UPMC, Paris, France.

Oncogene
|January 19, 2011
PubMed

Insights

Activating mutations in anaplastic lymphoma kinase (ALK) cause impaired maturation and intracellular retention of the receptor. This suggests potential therapeutic strategies using kinase inhibitors and antibodies for ALK-dependent tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase (RTK).
  • ALK is implicated in neuroblastoma predisposition and sporadic tumor development.
  • Specific ALK mutations (F1174L, R1275Q) are observed in neuroblastoma.

Purpose of the Study:

  • To investigate the cellular localization and activation of mutated ALK variants.
  • To understand the impact of ALK mutations on receptor maturation and trafficking.
  • To explore therapeutic strategies for ALK-dependent neuroblastoma.

Main Methods:

  • Utilized stably transfected cell lines expressing wild-type and mutated ALK.
  • Analyzed neuroblastoma cell lines with amplified mutated ALK.
  • Employed immunofluorescence, glycosylation assays, and monoclonal antibodies (agonist/antagonist).
  • Investigated the effect of kinase inactivation on ALK localization.

Main Results:

  • Mutated ALK variants exhibited intracellular retention, primarily in the endoplasmic reticulum/Golgi.
  • A defect in N-linked glycosylation was observed for mutated ALK.
  • Constitutively active mutated ALK showed impaired maturation and cell-surface localization.
  • Kinase inactivation restored ALK maturation and cell-surface targeting.

Conclusions:

  • Constitutive ALK activation leads to impaired receptor maturation and intracellular retention.
  • These findings support the use of kinase inhibitors and antibodies for treating ALK-dependent tumors.
  • Understanding ALK trafficking defects provides a rationale for targeted therapies.

Related Concept Videos

The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Mutations01:39

Mutations

Overview
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
GPCR Desensitization01:12

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...